Sage Journals: Discover world-class research

Abstract

The dog is the only species, other than humans, in which spontaneous prostatic cancer occurs; therefore, dogs are a valuable model for the study of factors that regulate tumor progression. Angiogenesis is important in the development and spread of a variety of cancers, including prostate cancer. To better define the role of cancer epithelial cells in prostate cancer neovascularization, immunohistochemical staining for angiogenic factors (vascular endothelial growth factor [VEGF], platelet endothelial cell adhesion molecule–1 [PECAM-1], Tie-2, and fibroblast growth factor–2 [FGF-2]) was performed on formalin-fixed, paraffin-embedded tissues from 10 normal prostates, 15 hyperplastic prostates, and 11 prostatic carcinomas from dogs. Normal and hyperplastic epithelial cells were negative for PECAM-1, VEGF, and Tie-2, while the same markers were expressed with a variable intensity of cytoplasmic staining by neoplastic cells. Mild to moderate FGF-2 staining was detected in all normal prostates with less than 10% of positive cells, mainly distributed in the basal layer. The percentage of FGF-2–positive hyperplastic cells was variable, with both basal and secretory cells exhibiting a perinuclear to diffuse cytoplasmic staining. The mean number of positive cells and the intensity of staining were higher in prostatic carcinomas than normal and hyperplastic prostates. Moreover, microvessel density analyzed on PECAM-1–stained slides was increased in prostate cancer compared with normal and hyperplastic prostates. Therefore, prostatic neoplastic cells are capable of simultaneous expression of various angiogenic factors and may increase tumor proliferation and angiogenesis in a paracrine and autocrine fashion.

Keywords

angiogenesis carcinoma dog hyperplasia immunohistochemistry prostate

Prostate cancer is the second leading cause of cancer-related death after lung cancer in men, and its incidence is steadily increasing in almost all countries.⁹ Prostate cancer progression occurs in 2 stages, the first being androgen responsive and the second androgen independent with a high metastatic rate.¹⁹ Dog prostates share anatomic and functional similarities with humans²⁸ and commonly and spontaneously develop benign prostatic hyperplasia (BPH),²⁹ high-grade prostatic intraepithelial neoplasia (HGPIN), and prostate cancer.⁵¹ Thus, dogs are a highly relevant animal model of prostatic cancer.

The development of prostate cancer includes a multistep program of genetic alterations in pathways affecting cell cycle, apoptosis, adhesion, motility, and angiogenesis. It is well known that the angiogenic switch is vital for tumor growth and progression.^3,15 Cancer cells stimulate angiogenesis either by directly secreting growth factors and cytokines that act on the endothelial cells of adjacent vessels and microvessels or by activating angiogenic compounds in the extracellular matrix.⁶

Different angiogenic proteins are overexpressed in solid tumors, therefore representing a potential target in the management of cancer. Vascular endothelial growth factor (VEGF), one of the most potent angiogenic factors, is expressed in normal human prostatic epithelium,^4,5,22,23 BPH,^20,22,50 and prostatic carcinomas^22,50,53 with variable intensity of staining. Nonneoplastic tissue has shown a low number of positively stained epithelial cells,^50,53 if not absence or weak immunoreactivity.^12,13 Tumor staining appears to correlate with degree of differentiation, with the highest expression in poorly differentiated human prostate cancers.^12,13

Basic fibroblast growth factor (bFGF or FGF-2) has attracted special attention for its angiogenic properties and for acting as a powerful mitogen stimulating cell differentiation and proliferation.¹⁸ FGF-2 has broad biological functions that can play an important role in tumorigenesis, such as increasing motility and invasiveness,²⁵ as well as acting as an autocrine growth factor and stimulating the progression toward malignancy.⁴³ FGF-2 could also affect the cytotoxicity of chemical and other nonphysiological stresses inflicted on the cells, and this is particularly important for the interaction of cancer cells with chemotherapeutic drugs and other DNA-damaging agents.⁵⁶ In humans, results on immunolocalization of FGF-2 in nonneoplastic prostates are controversial, and the role of FGF-2 in prostatic carcinoma is still unclear,^16,37,46,49 although FGF-2 concentration has been shown to be elevated in the serum of affected patients.³¹

The immunohistochemical expression of platelet endothelial cell adhesion molecule–1 (PECAM-1) or CD31^7,8 by endothelial cells has been extensively used for analyzing the microvascular density of human prostatic carcinoma,⁴¹ while no reports are available on the potential expression of this marker in neoplastic epithelial cells.

Tie-2 is an endothelial cell-specific tyrosine kinase receptor expressed in the vascular system from the early stages of embryogenesis,⁴⁵ whose expression has been recently described in hematopoietic precursors and neoplastic cells in human cancers.^35,48

To better define the role of angiogenic factors in canine prostatic diseases, especially canine prostatic carcinoma, this study analyzes the immunohistochemical expression of VEGF, FGF-2, PECAM-1, and Tie-2 in canine normal, hyperplastic, and carcinomatous epithelial cells.

Materials and Methods

Study Samples

Thirty-six formalin-fixed, paraffin-embedded canine prostatic samples were selected from the archive of the diagnostic pathology service of the School of Veterinary Science, The University of Queensland. The hematoxylin and eosin–stained sections were reexamined by an experienced pathologist (C.P.) to confirm the histopathological diagnosis. Ten normal canine prostates from adult dogs, 15 samples of BPH, and 11 prostatic carcinomas were studied. BPH and prostatic carcinomas were derived from dogs ranging in age from 3 to 11 years and from 6 to 12 years, respectively. The most affected breeds were German Shepherd (3), Rottweiler (2), and Scottish Terrier (2) for BPH and German Shepherd (3) and Doberman Pinscher (2) for prostatic carcinoma.

Histology

Prostatic carcinomas were classified according to the growth patterns described by Lai et al:²⁶ micropapillary (papillary projections of neoplastic cells within extended ducts, which lack a distinct fibrovascular core), cribriform (ducts completely filled by neoplastic cells forming regular fenestrae with frequent central necrosis or comedonecrosis), solid (solid nests or individual anaplastic cells), sarcomatoid (neoplastic cells with a spindle morphology), small acinar/ductal (acinar structures within a scirrhous fibromuscular stroma), or tubulopapillary (dilated ducts with single to stratified layers of columnar cells).

Immunohistochemistry

The immunohistochemical procedure is provided in detail in Supplemental Material 1.

Evaluation of Immunohistochemistry (VEGF, PECAM-1, Tie-2, FGF-2) in Normal, Hyperplastic, and Carcinomatous Prostatic Epithelial Cells

A semiquantitative and a qualitative immunohistochemical assessment were performed as detailed in Supplemental Material 1.

Microvessel Density

Microvessel density (MVD) was analyzed in benign and malignant prostatic tissue by counting the average number of PECAM-1–positive vessels, as previously described⁵² and detailed in Supplemental Material 1.

Statistical Analysis

Differences among the 3 groups were assessed by the χ² test and considered significant at P < .001.

Results

Histology

In the normal prostates, small to medium glands lined by a single layer of cuboidal to columnar cells forming occasional short papillary infoldings were present. BPH was characterized by epithelial hyperplasia, cystic dilation, and mild fibrosis. The most common types of prostatic carcinomas were cribriform (6 of 11; dog Nos. 26, 28, 33, 34, 35, 36) with comedonecrosis in 5 cases (dog Nos. 26, 28, 34, 35, 36) and small acinar/ductal (3 of 11; dog Nos. 29, 31, 32). A prevalent solid pattern with multifocal sarcomatoid areas (dog No. 27) and a micropapillary pattern (dog No. 29) were observed in 1 case each. Metastases were detected in 1 case (dog No. 27) in the lung, lymph nodes, and kidney.

Immunohistochemistry

In all samples, positive staining was observed in the fibrovascular stroma (VEGF, FGF-2) and blood vessel endothelium (VEGF, FGF-2, PECAM-1, Tie-2). The results of the immunohistochemical analysis are provided in the Supplemental Table S1.

Normal and hyperplastic epithelial cells were negative for PECAM-1 (Fig. 1), VEGF, and Tie-2. PECAM-1 was expressed in all 11 prostatic carcinomas with a weak (8 cases) to moderate (3 cases) cytoplasmic staining (Fig. 2) and a variable semiquantitative score. Tie-2 expression was detected in 9 of 11 prostatic carcinomas (Fig. 3), with a percentage of labeled neoplastic cells ranging from >0% to <10% (5 cases) to ≥10% to <25% (3 cases). The intensity of staining was mild to moderate. In prostatic carcinoma, VEGF-positive neoplastic cells (Fig. 4) were lower in number compared with Tie-2 and PECAM-1–positive cells, with a multifocal, randomly scattered cytoplasmic expression in less than 10% of cells in 8 of 11 samples and 10% to 25% of cells in 1 sample. Two cases were negative. Most of the neoplastic cells demonstrated a mild staining reaction.

Figure 1.

Benign prostatic hyperplasia; dog No. 15. The immunohistochemical signal is limited to the blood vessel endothelium. Epithelial cells are negative. Inset: platelet endothelial cell adhesion molecule–1 (PECAM-1) immunostaining of endothelial cells. Immunohistochemistry (IHC) for PECAM-1. Figure 2. Prostatic carcinoma; dog No. 26. Diffuse labeling of PECAM-1 in the cytoplasm of neoplastic epithelial cells. IHC for PECAM-1. Figure 3. Prostatic carcinoma; dog No. 26. Tie-2–positive neoplastic cells of a cribriform carcinoma with comedonecrosis. Note the granular cytoplasmic staining. IHC for Tie-2. Figure 4. Prostatic carcinoma; dog No. 28. Weak multifocal cytoplasmic vascular endothelial growth factor (VEGF) immunoreactivity of neoplastic epithelial cells. IHC for VEGF. Figure 5. Normal prostate; dog No. 3. Randomly scattered fibroblast growth factor–2 (FGF-2)–positive epithelial cells, mainly distributed in the basal layer. IHC for FGF-2. Figure 6. Benign prostatic hyperplasia; dog No. 14. High number of FGF-2–positive secretory and basal cells with a granular perinuclear to diffuse staining pattern. IHC for FGF-2. Figure 7. Prostatic carcinoma; dog No. 28. Aggregates of neoplastic epithelial cells surrounded by fibrous reaction: diffuse moderate to strong FGF-2 immunoreactivity. IHC for FGF-2. Figure 8. Prostatic carcinoma; dog No. 32. Multifocal labeling of FGF-2 in neoplastic epithelial cells. IHC for FGF-2.

FGF-2 was expressed in each group of prostate samples but differed in the semiquantitative and qualitative score. A mild to moderate cytoplasmic staining was detected in normal prostates (Fig. 5) with less than 10% positive cells, mainly distributed in the basal layer. In 2 of 10 normal prostates, occasional (1%–2%) randomly scattered FGF-2–positive cells were observed. A variable staining characterized BPH, with less than 10% (4/15), ≥10% to <25% (4/15), ≥25% to <50% (4/15), and ≥50% to <75% (3/15) cells. Both basal and secretory cell types were positive (Fig. 6), with a prevalent perinuclear pattern in the latter. The mean number of positive cells and the intensity of staining were higher in prostatic carcinomas (Fig. 7, 8) than in normal and hyperplastic prostates, with a semiquantitative score of 4+ in 6 of 11 cases, 5+ in 3 of 11 cases, and 3+ in 2 of 11 cases. The protein was diffusely distributed within the cytoplasm of neoplastic cells. Supplemental Figures S1 to S12 show the expression of the 4 different markers (PECAM-1, Tie-2, VEGF, FGF-2) in each prostatic carcinoma subtype.

The final immunohistochemical score of the FGF-2, PECAM-1, Tie-2, and VEGF expression in normal, hyperplastic, and carcinomatous prostatic epithelial cells is summarized in Table 1. The FGF-2 final score was significantly different between normal and hyperplastic prostates and between normal prostates and carcinomas (P < .001). The difference in PECAM-1, Tie-2, and VEGF expression was statistically significant between prostatic carcinomas and both normal and hyperplastic prostates (P < .001).

Table 1.

Immunohistochemical Score of FGF-2, PECAM-1, Tie-2, and VEGF Expression in Normal, Hyperplastic (BPH), and Carcinomatous (PC) Prostatic Epithelial Cells (Mean ± SD).

Diagnosis	FGF-2	PECAM-1	Tie-2	VEGF
Normal prostate (n = 10)	1.2 ± 0.38	0	0	0
BPH (n = 15)	5.07 ± 2.76	0	0	0
PC (n = 11)	8.09 ± 2.89	2.09 ± 1.03	1.81 ± 1.40	1.09 ± 0.67

BPH, benign prostatic hyperplasia; FGF-2, fibroblast growth factor–2; PC, prostate cancer; PECAM-1, platelet endothelial cell adhesion molecule–1; VEGF, vascular endothelial growth factor.

Microvessel Density

The analysis of the microvessel density by PECAM-1 showed a statistically significant (P < .001) increase in the number of microvessels in prostate cancer (mean ± SD, 65.03 ± 6.63) compared with normal (11.02 ± 1.66) and BPH tissues (40.55 ± 69.23).

Discussion

This study suggests that canine prostatic carcinoma cells are capable of simultaneous production of various angiogenic factors (VEGF, PECAM-1, Tie-2) that are not expressed in normal or hyperplastic prostatic epithelial cells. Moreover, the increased expression of angiogenic factors by neoplastic cells is associated with an increased number of blood vessels.

VEGF is expressed by endothelial cells, tumor stromal cells, and prostate cancer cells, as already demonstrated in humans.^12,13,20 VEGF produced by neoplastic cells stimulates angiogenesis by acting in a paracrine fashion on adjacent endothelial cells. However, as vascular endothelial growth factor receptor (VEGFR)–1 and VEGFR-2 are also expressed by various human cancer cell lines, including prostate cancer cells,¹⁴ VEGF may also act in an autocrine fashion to modulate tumor growth. Culture of the prostate cancer cell line LNCaP in the presence of recombinant human VEGF165 resulted in a 50% increase in ^[3H]thymidine uptake by these cells and recruitment of quiescent cells into the cell cycle.²³ Moreover, in humans, increased expression of VEGF in malignant cells during the transition from high-grade prostatic intraepithelial neoplasia to invasive carcinoma leads to an epithelial mesenchymal transition (EMT) through an autocrine loop that would promote tumor cell invasion and motility.¹⁷ The author (C.P.) and others have recently described a redistribution of β-catenin in addition to an increased expression of mesenchymal markers in prostate cancer cells,^27,42 suggesting that EMT occurs during the progression of canine prostatic carcinoma. Therefore, the therapeutic blockade of VEGF could be a strategy for impairing tumor angiogenesis and early invasiveness of malignant cells.

The results of this study demonstrate that FGF-2 could be of importance in the induction of hyperplastic lesions and in the progression of prostatic carcinoma in dogs, while it is likely not involved in normal prostatic homeostasis. In humans, FGF-2 expression in normal and pathological prostates is controversial, with positive reactions demonstrated by some investigators in normal and hyperplastic prostates^{1,10,34,36,40,44} and in rat and human prostate cancer cell lines,^37,46 and failed evidence of staining in prostatic neoplastic cells in other studies.^16,49 The different immunoreactivity of prostate cancer samples across different studies can be related to the neoplastic stage. Two research groups, using tissues from more advanced cancers, have detected the expression of FGF-2 in human prostate cancer epithelial cells in the majority of cases.^5,11 High levels of expression of FGF-2 are present in PC3 and Du145 prostate cancer cells,^5,37 and both of these cell lines are derived from metastatic prostate cancer. Thus, it may be suggested that FGF-2 is initially expressed as a paracrine factor by stromal cells in localized prostatic carcinoma but switches to an autocrine expression during tumor progression. This hypothesis is supported in the present study considering that prostatic carcinoma is a biologically aggressive neoplasm in dogs, and affected animals frequently have advanced cancer at the time of diagnosis.²

PECAM-1 expression by cancer cells and lack of expression in normal or hyperplastic epithelia implies that this protein is acquired by epithelial cells during neoplastic transformation. The presence of PECAM-1 in malignant epithelial cells could be explained in the context of vasculogenic mimicry (VM).^21,30 Based on this theory, specific tumor elements form blood-filled channels and become intensely PECAM-1 positive at least in the experimental setting of uveal melanoma.³⁰ Vasculogenic mimicry has been seen in several human malignant tumors, such as breast cancer, liver cancer, glioma, ovarian cancer, melanoma, and prostate cancer,⁵⁵ and in 38% of canine mammary tumors.¹⁰ Although still a topic of discussion in prostate cancer, this model is challenging. Channels formed by tumor cells were detected in human prostatic carcinoma (Gleason grade 5).⁴⁷ The precise mechanism triggering the upregulation of PECAM-1 in neoplastic cells is not known. PECAM-1 expression in prostate cancer might be the result of gene amplification, as suggested for human breast cancer, in which 17q23 (the region of the chromosome where CD31 gene is localized) is frequently amplified.³² Not surprisingly, 17q23-24 amplification has been demonstrated in human prostatic carcinoma.²⁴

In humans, Tie-2 expression has been reported in different types of tumors, such as leukemia, prostate cancer, giant cell tumor of tendon sheath, and gastric, colorectal, and endometrial carcinoma,^{33,35,38,39,48,49,54} although the precise function of Tie-2 expressed in tumor cells remains unclear. In 69% of human gastric carcinomas, the expression of Tie-2 was inversely correlated with the degree of histological differentiation, degree of stromal reaction, and tumor growth pattern.³⁹ However, the expression of Tie-2, as well as other angiogenic factors, was not correlated with tumor grade, degree of differentiation, and histological subtypes in the present study.

This study suggests the production and overexpression of angiogenic factors by neoplastic prostatic epithelial cells may increase angiogenesis and potentially tumor proliferation. However, many questions remain to be answered, including the mechanism by which expression of these factors is regulated in prostate cancer cells. Their expression can be modulated by transcriptional, posttranscriptional, and translational mechanisms, but little is known about what underlies the expression of them as autocrine growth factors in prostate cancer cells. Although many of these factors are pleiotropic and probably serve functions unrelated to angiogenesis, these cells appear to possess a redundant, overlapping capacity for inducing neovascularization. This finding of multiple angiogenic factors complicates the issue of how one could therapeutically control the angiogenic process in prostate carcinoma. Therefore, further studies on the identification of regulatory pathways are required to develop antiangiogenic strategies.

Footnotes

Supplemental material for this article is available on the Veterinary Pathology website at .

Acknowledgement

I thank Dr Rachel Allavena of the School of Veterinary Science (The University of Queensland) for invaluable assistance in reviewing and editing the manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Begun

Story

Hopp

. Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol. 1995;153(3, pt 1):839–843.

Bell

Klausner

Hayden

. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970–1987). J Am Vet Med Assoc. 1991;199(11):1623–1630.

Brawer

. Quantitative microvessel density: a staging and prognostic marker for human prostatic carcinoma. Cancer. 1996;78(2):345–349.

Clemente

Pérez-Alenza

Illera

. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet Pathol. 2010;47 (2):265–274.

Cronauer

Hittmair

Eder

. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate. 1997;31 (4):223–233.

de la Taille

Katz

Bagiella

. Microvessel density as a predictor of PSA recurrence after radical prostatectomy: a comparison of CD34 and CD31. Am J Clin Pathol. 2000;113 (4):555–562.

Deaglio

Mallone

Baj

. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol. 2000;75:99–120.

DeLisser

Newman

Albelda

. Molecular and functional aspects of PECAM-1/CD31. Immunol Today. 994;15(10):490–495.

Delongchamps

Peyromaure

Dinh-Xuan

. Role of vascular endothelial growth factor in prostate cancer. Urology. 2006;68 (2):244–248.

10.

Deshmukh

Scotson

Dodson

. Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol. 1997;80:869–874.

11.

Dorkin

Robinson

Marsh

. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol. 1999;189 (4):564–569.

12.

Ferrer

Miller

Andrawis

. Vascular endothelial growth factor (VEGF) expression in human prostate cancer. J Urol. 1997;157:2329–2333.

13.

Ferrer

Miller

Andrawis

. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 1998;51:161–167.

14.

Ferrer

Miller

Lindquist

. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54 (3):567–572.

15.

Folkman

. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev. 1990;9 (3):171–174.

16.

Giri

Ropiquet

Ittmann

. Alterations in expression of basic fibroblast growth factor (FGF)2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999;5:1063–1071.

17.

Gonzalez-Moreno

Lecanda

Green

. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)–like cells via an autocrine loop. Exp Cell Res. 2010;316 (4):554–567.

18.

Gospodarowicz

. Molecular and developmental biology aspects of fibroblast growth factor. Adv Exp Med Biol. 1988;234:23–39.

19.

Haq

Goltzman

Tremblay

. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow–derived endothelial cells. Cancer Res. 1992;52:4613–4619.

20.

Harper

Glynne-Jones

Goddard

. Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells. Br J Cancer. 1996;74:910.

21.

Hendrix

Seftor

Meltzer

. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A. 2001;98:8018–8023.

22.

Jackson

Bentel

Tilley

. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997;157:2323–2328.

23.

Jackson

Roberts

Heckford

. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 2002;62 (3):854–859.

24.

Kasahara

Taguchi

Yamasaki

. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet. 2002;137:59–63.

25.

Kwabi-Addo

Ozen

Ittmann

. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11 (4):709–724.

26.

Lai

van den Ham

van Leenders

. Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate. 2008;68 (5):477–488.

27.

Lean

Kontos

Palmieri

. Expression of β-catenin and mesenchymal markers in canine prostatic hyperplasia and carcinoma. J Comp Pathol. 2014;150 (4):373–381.

28.

Leroy

Northrup

. Prostate cancer in dogs: comparative and clinical aspects. Vet J. 2009;180 (2):149–162.

29.

Mahapokai

Van Sluijis

Schalken

. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2000;3 (1):28–33.

30.

Maniotis

Folberg

Hess

. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739–752.

31.

Meyer

Siegal

. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer. 1995;76 (11):2304–2311.

32.

Monni

Barlund

Mousses

. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A. 2001;98:5711–5716.

33.

Moon

Park

. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci. 2006;21:272–278.

34.

Mori

Maki

Oishi

. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate. 1990;16:71–80.

35.

Muller

Lange

Gaiser

. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leukemia Res. 2002;26:163–168.

36.

Mydlo

Michaeli

Heston

. Expression of basic-fibroblast-growth-factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Cancer. 1988;13:241–247.

37.

Nakamoto

Chang

. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 1992;52:571–577.

38.

Nakashima

Uchida

Tsukazaki

. Expression of tyrosine kinase receptors Tie-1 and Tie-2 in giant cell tumor of the tendon sheath: a possible role in synovial proliferation. Pathol Res Pract. 2001;197:101–107.

39.

Nakayama

Yoshizaki

Kawahara

. Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology. 2004;44 (3):232–239.

40.

Nishi

Matuo

Kunitimo

. Comparative analysis of growth factors in normal and pathologic human prostates. Prostate. 1988;12:343–355.

41.

Ozerdem

Wojcik

Duan

. Prognostic utility of quantitative image analysis of microvascular density in prostate cancer. Pathol Int. 2013;63 (5):277–282.

42.

Rodrigues

Rema

Gartner

. Overexpression of vimentin in canine prostatic carcinoma. J Comp Pathol. 2011;144 (4):308–311.

43.

Ropiquet

Berthon

Villette

J-M

. Constitutive expression of FGF2/bFGF in non tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype. Int J Cancer. 1997;72:543–547.

44.

Saez

Gonzalez-Baena

Japon

. Expression of basic fibroblast growth factors and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate. 1999;40:83–88.

45.

Sato

Qin

Kozak

. Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A. 1993;90:9355–9358.

46.

Shain

Lin

Wong

. Signal transduction defect appears to be the cause of rat prostate cancer cell fibroblast growth factor insensitivity. Cell Growth Differ. 1992;3 (10):715–722.

47.

Sharma

Seftor

. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002;50 (3):189–201.

48.

Shaw JP Basch

Shamamian

. Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells Mol Dis. 2004;32:168–175.

49.

Sinowatz

Amselgruber

Lincoln

. The role of basic fibroblast growth factor in prostatic tumors. Nutrition. 1995;11:619–621.

50.

Trojan

Thomas

Knoll

. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res. 2004;32:97–103.

51.

Waters

Bostwick

. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res. 1997;17 (3A):1467–1470.

52.

Weidner

Carroll

Flax

. Tumor angiogenesis correlated with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409.

53.

Woollard

Opeskin

Coso

. Differential expression of VEGF ligands and receptors in prostate cancer. Prostate. 2013;73 (6):563–572.

54.

Wurmbach

Hammemmer

Sevinc

. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 2000;20:5217–5220.

55.

Zhang

Sun

. Vasculogenic mimicry: current status and future prospects. Cancer Lett. 2007;254 (2):157–164.

56.

Zhang

Song

Yang

. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther. 2001;299:426–433.

Immunohistochemical Expression of Angiogenic Factors by Neoplastic Epithelial Cells Is Associated With Canine Prostatic Carcinogenesis

Abstract

Keywords

Materials and Methods

Study Samples

Histology

Immunohistochemistry

Evaluation of Immunohistochemistry (VEGF, PECAM-1, Tie-2, FGF-2) in Normal, Hyperplastic, and Carcinomatous Prostatic Epithelial Cells

Microvessel Density

Statistical Analysis

Results

Histology

Immunohistochemistry

Microvessel Density

Discussion

Footnotes

Acknowledgement

Declaration of Conflicting Interests

Funding

References